Ibrutinib/buparlisib looks good for relapsed mantle cell lymphomaJune 27, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Pembrolizumab + rituximab boost response rates in relapsed follicular lymphomaJune 26, 2017ImmunotherapyLymphoma & Plasma Cell DisordersFollicular Lymphoma
CARs race for supremacy against aggressive non-Hodgkin lymphomaJune 25, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Twofer drug blocks SYK/JAK pathways in advanced NHLJune 23, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
FDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLLJune 22, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersFollicular Lymphoma
Lenalidomide-rituximab induces high CR rate in untreated follicular lymphomaJune 21, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
GALEN safe and effective in relapsed and refractory follicular lymphomaJune 20, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Subcutaneous rituximab safe, effective for follicular lymphomaMay 9, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
In mantle cell lymphoma, triple therapy proves too toxicApril 24, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Thousands expected to get CAR T-cells by 2018April 20, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Obinutuzumab vs. rituximab weighed as follicular lymphoma therapyApril 18, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
Reduced-intensity conditioning may not preserve fertility in young girls after bone marrow transplantApril 17, 2017PediatricsFollicular Lymphoma
CAR designers report high B-cell cancer response ratesMarch 2, 2017Leukemia, Myelodysplasia, TransplantationFollicular Lymphoma
Circulating DNA catches lymphoma relapse earlyJanuary 29, 2017Lymphoma & Plasma Cell DisordersFollicular Lymphoma
VIDEO: Obinutuzumab bests rituximab for PFS in follicular lymphomaDecember 6, 2016Lymphoma & Plasma Cell DisordersFollicular Lymphoma
